QHSLab (USAQ) AI Stock Analysis

• Market Cap: $9.59M
• Dividend Yield: N/A
• Average Volume (3M): 6.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 43.55%
• EPS Growth: -461.90%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 11,281,527
• 10 Day Avg. Volume: 9,209
• 30 Day Avg. Volume: 6,568
• PEG Ratio: 0.20
• Price to Book (P/B): -4.20
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 17.91
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: 1.45
• Enterprise Value/Gross Profit: 2.18
• Enterprise Value/Ebitda: 13.59
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.2
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $0.88 ▲(79.59% Upside)

The score is held back primarily by weaker financial quality—especially negative equity and continued net losses—despite improving revenue, margins, and positive free cash flow. Technicals are strong (price above all key moving averages with positive MACD) but appear overextended (high RSI/Stoch). Corporate events are supportive due to meaningful deleveraging and added liquidity, while valuation remains constrained by a negative P/E and no dividend.

Positive Factors

Revenue Growth Momentum

Sustained top-line growth (32% YoY for nine months) signals improving market traction for QHSLab’s digital health offerings. Durable revenue expansion over multiple quarters improves the company's ability to scale sales and absorb fixed costs, supporting longer-term profitability if growth continues.

High Gross Margins

A ~66% gross margin is structurally supportive for a software-enabled medical device/digital health model, enabling strong markups on incremental revenue. High gross margins create room for investment in sales and R&D while helping sustain operating profits as revenue scales over the medium term.

Deleveraging and Added Liquidity

Material retirement of high-cost convertible notes plus a ~$500k equity raise and ~$630k cash balance meaningfully reduce interest expense and near-term dilution risk. This strengthens the capital structure and extends runway, allowing management to focus on scaling recurring revenues rather than urgent refinancing.

Negative Factors

Negative Stockholders' Equity

Negative equity is a structural balance-sheet weakness that limits financial flexibility and increases solvency risk. It constrains access to traditional credit, raises refinancing risk during downturns, and makes the company more dependent on dilutive equity or conditional financing to fund growth.

Persistent Net Losses

Although operating profit improved, the company remains net loss-making on a TTM basis (~-15% margin). Persistent net losses impair retained earnings, limit reinvestment capacity, and may necessitate continued external financing, making sustainable profitability a key medium-term execution risk.

Thin Cash Conversion and Small Scale

Positive free cash flow is encouraging, but low cash conversion versus revenue leaves limited buffer for shocks or growth investment. Combined with modest total assets and a small employee base, the business remains operationally small and vulnerable to margin pressure or customer concentration risk over the coming months.

QHSLab Business Overview & Revenue Model

Company Description

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.

How the Company Makes Money

USA Equities makes money primarily through the sale of its medical devices and digital healthcare solutions. The company's revenue streams include direct sales to healthcare providers and institutions, licensing agreements for its proprietary technologies, and subscription-based services for its digital health platforms. Key partnerships with medical distributors and healthcare organizations also contribute to its earnings. By leveraging these relationships and its innovative product offerings, USA Equities is able to generate revenue and sustain its business operations.

QHSLab Financial Statement Overview

Summary

USA Equities exhibits strong revenue growth and improved cash flow but is hampered by high leverage and persistent losses. The company's negative equity and profitability issues present financial risks, though revenue growth and positive free cash flow indicate potential for a turnaround.

Income Statement

USA Equities has shown significant revenue growth with a 51.3% increase from 2023 to 2024. However, the net profit margin remains negative at -12.16% in 2024, indicating ongoing profitability challenges. The gross profit margin improved to 63.7%, but the EBIT margin of 9.65% reflects operational inefficiencies. The company has made progress, but consistent profitability remains a hurdle.

Balance Sheet

The company is highly leveraged with a negative stockholders' equity of -$607,756 in 2024, resulting in an undefined debt-to-equity ratio. The equity ratio is also negative due to negative equity, posing a risk to financial stability. Despite a reduction in total liabilities, the negative equity position indicates potential solvency issues.

Cash Flow

There is a strong improvement in free cash flow, turning positive in 2024 at $142,437, from a negative position the previous year. The operating cash flow to net income ratio is negative due to losses, but the cash flow indicates better cash management. Sustaining positive cash flow will be crucial for future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.61M	2.13M	1.41M	1.24M	1.41M	124.53K
Gross Profit	1.73M	1.36M	793.61K	619.52K	670.75K	50.09K
EBITDA	278.24K	352.39K	-91.29K	-434.60K	-487.63K	-296.40K
Net Income	-386.75K	-259.24K	-468.36K	-996.00K	-770.18K	-327.39K
Balance Sheet
Total Assets	1.73M	1.80M	1.68M	1.96M	2.21M	297.86K
Cash, Cash Equivalents and Short-Term Investments	158.39K	157.17K	51.58K	178.69K	286.86K	94.34K
Total Debt	1.21M	1.72M	1.78M	1.68M	1.30M	631.00K
Total Liabilities	2.35M	2.41M	2.06M	1.88M	1.38M	906.19K
Stockholders Equity	-610.91K	-607.76K	-375.62K	76.25K	824.07K	-608.33K
Cash Flow
Free Cash Flow	135.13K	142.44K	-159.63K	-388.11K	-509.31K	-197.26K
Operating Cash Flow	135.13K	142.44K	-159.63K	-350.99K	-354.74K	-165.56K
Investing Cash Flow	0.00	0.00	0.00	-37.12K	-154.57K	-31.70K
Financing Cash Flow	-72.69K	-36.85K	32.52K	279.95K	701.82K	268.02K

QHSLab Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.49
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.49 is below the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.34, and above the 200-day MA of 0.23, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 70.86 is Negative, neither overbought nor oversold. The STOCH value of 62.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.

QHSLab Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
USAQ	57 Neutral	$9.59M	-23.13	―	―	43.55%	-461.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEMD	45 Neutral	$2.39M	-0.05	-191.39%	―	―	76.53%
NUWE	43 Neutral	$3.27M	-0.02	-467.14%	―	-8.93%	97.80%
VTAK	42 Neutral	$3.38M	-0.05	-173.74%	―	82.96%	82.04%
VERO	40 Underperform	$2.84M	-0.03	-854.61%	―	-12.39%	44.61%

QHSLab Corporate Events

QHSLab Reports Strong 2025 Growth and Deleveraged Balance Sheet

On January 6, 2026, QHSLab issued an unaudited financial and operational update ahead of an investor session, reporting that revenue for the nine months ended September 30, 2025 rose 32% year over year to $1.99 million, with gross profit of $1.32 million at a 66% margin, net operating income before interest of $95,738, and approximately $630,000 in cash as of December 31, 2025. During the fourth quarter of 2025, the company nearly eliminated its outstanding convertible debt, cutting it from about $1.4 million to $20,000 and thereby significantly reducing interest expense, while management indicated the business exited 2025 in a cash-flow-positive operating position and highlighted a capital structure consisting of 13.4 million shares outstanding, a relatively small public float, and a sizable block of restricted shares from recent financings and debt conversions.

The most recent analyst rating on (USAQ) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.

QHSLab Modifies Debt and Converts Note to Equity

On December 31, 2025, QHSLab, Inc. entered into a Promissory Note Modification and Partial Conversion Agreement with creditor Alex Mirakian MD PA, under which $126,548 of a previously issued convertible note’s principal and accrued interest was converted into 421,827 shares of QHSLab common stock at $0.30 per share, leaving $20,000 outstanding. The company extended the maturity date of the remaining balance to December 31, 2026, kept the original conversion features on the residual debt, and preserved the right to prepay without penalty, while issuing the new shares in a private, exempt transaction that reduces debt but dilutes existing shareholders and modestly strengthens QHSLab’s balance sheet.

The most recent analyst rating on (USAQ) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.

QHSLab strengthens balance sheet with new equity financing

On December 26, 2025, QHSLab raised approximately $500,000 in a private placement of common stock and warrants to two accredited investors, issuing about 1.67 million shares at $0.30 per share and 416,666 warrants exercisable at $0.60 through 2030, with net proceeds of more than $495,000 earmarked for general corporate purposes and working capital. Announced publicly on December 29, 2025, the financing followed the November 2025 repurchase and retirement of more than $1.4 million in high-cost legacy convertible notes, eliminating several million shares of potential dilution and over $200,000 in annual interest expense; together, the debt retirement and new equity capital materially improve QHSLab’s liquidity and capital structure, allowing management to shift focus toward scaling its digital health offerings, expanding its physician client base and driving recurring revenue growth, against a backdrop of 32% year-over-year revenue growth and a 66% gross margin for the first nine months of 2025.

QHSLab Launches Q-Cog™ for Early Dementia Detection

On December 3, 2025, QHSLab announced the launch of Q-Cog™, a cloud-based cognitive assessment tool designed to aid primary care providers in the early detection of Mild Cognitive Impairment and dementia. The tool combines cognitive, behavioral, and functional screening within a digital workflow, aligning with CMS guidelines and supporting value-based care. In a pilot study, Q-Cog™ identified 54% of 168 patients aged 65 and older as high-risk for cognitive impairment, highlighting the tool’s potential to fill a critical gap in early dementia detection and create new revenue opportunities for QHSLab and its partners.

QHSLab Releases December 2025 Corporate Presentation

QHSLab, Inc. released its December 2025 Corporate Presentation on December 1, 2025, detailing its business and operations. The presentation, furnished under Regulation FD, emphasizes the company’s commitment to transparency and the use of various platforms for public information dissemination, highlighting its strategic approach to investor relations and stakeholder engagement.

QHSLab Reports Strong Revenue Growth and Debt Reduction

QHSLab, Inc. reported a transformational year in 2025, marked by significant revenue growth and a strengthened balance sheet, as highlighted in their recent shareholder letter. The company achieved $1.99 million in revenue for the first nine months of 2025, a notable increase from the previous year, and eliminated a major source of dilution by retiring convertible notes. This strategic move removed over $1.4 million in liabilities and protected shareholders from potential market dilution, positioning QHSLab for strong growth in 2026 with a focus on expanding digital health revenues and enhancing operational efficiency.

QHSLab Retires Convertible Debt, Strengthens Financial Position

On November 18, 2025, QHSLab, Inc. completed a Note Repurchase Agreement to retire over $1.4 million in defaulted convertible debt, originally issued in 2021 and 2022, for a cash payment of $300,000. This strategic move strengthens QHSLab’s balance sheet, reduces future dilution risks, and eliminates conversion rights, positioning the company for healthier financial growth. The company reported a 35% increase in Q3 2025 revenue, reflecting strong operational momentum and effective technology deployment in primary care settings.